Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.
Harmony Biosciences Holdings, Inc. develops and commercializes therapies for rare neurological diseases, with WAKIX® (pitolisant) as its commercial product for adult narcolepsy-associated cataplexy. News about HRMY centers on WAKIX revenue trends, market access and payer dynamics, intellectual-property protection, and product guidance.
Company updates also cover clinical and regulatory progress across its CNS pipeline, including pitolisant lifecycle programs and candidates such as EPX-100 for Dravet syndrome and Lennox-Gastaut syndrome. Recurring announcements include quarterly results, investor-conference presentations, executive and board changes, and pipeline data presentations at medical meetings.
Harmony Biosciences Holdings (HRMY) announced the recipients of the second-annual Patients at the Heart Grant on World Narcolepsy Day, September 22, 2020. This year, $74,000 was awarded to three organizations, an increase from $65,000 awarded in 2019 to four organizations. The initiative focuses on supporting programs that assist people with narcolepsy, particularly during the COVID-19 pandemic. Notable programs funded include digital support groups and resources aimed at improving the quality of life for individuals affected by narcolepsy.
Harmony Biosciences (Nasdaq: HRMY) presented post-hoc analyses of WAKIX® (pitolisant) data at the virtual SLEEP 2020 meeting, showcasing its efficacy and safety in treating narcolepsy. Key findings included significant improvements in excessive daytime sleepiness and cataplexy reduction compared to placebo, with significant time-to-response from Week 2. The analyses indicated a favorable cardiac safety profile for pitolisant, with no substantial cardiovascular risks observed. These results aim to assist healthcare professionals in treatment decisions for narcolepsy patients.
Harmony Biosciences (Nasdaq: HRMY) announced that it will present new safety and efficacy data on its narcolepsy treatment, WAKIX® (pitolisant), at the 34th Annual Meeting of the Associated Professional Sleep Societies, SLEEP 2020, from August 27-30, 2020. The presentations include findings from the Pitolisant Expanded Access Clinical Evaluation Program and analyses of pitolisant's cardiac safety profile. Harmony's Chief Medical Officer highlighted the importance of these analyses in providing important information for patients and healthcare providers.
Harmony Biosciences has completed its upsized IPO, successfully offering 6,151,162 shares of common stock at $24.00 per share, yielding gross proceeds of approximately $147.6 million. This offering included 802,325 shares sold under the underwriters' option. Shares began trading on the Nasdaq Global Market under the ticker symbol HRMY on August 19, 2020. The offering was led by Goldman Sachs, Jefferies, and Piper Sandler, with the registration statement declared effective on August 18, 2020.
Harmony Biosciences announced the pricing of its upsized initial public offering (IPO) of 5,348,837 shares at $24.00 each, aiming to raise a total of $128.4 million. The shares will start trading on the Nasdaq under the ticker symbol HRMY on August 19, 2020. An additional 802,325 shares may be purchased by underwriters within 30 days at the IPO price. This offering supports Harmony's mission of developing innovative therapies for rare neurological disorders and is expected to close on August 21, 2020, subject to customary conditions.